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Noninvasive prenatal testing (NIPT) enables the detection of common fetal aneuploidies such as
trisomy 21, trisomy 18, trisomy 13, and sex chromosome abnormalities via analysis of cell-free fetal
DNA circulating in maternal serum. Although the accuracy of NIPT for fetal aneuploidy is expected to be
higher than that of currently available alternative maternal serum screening options, the implications of
results are not straight forward. In October 2013, the option to screen for additional trisomies and select
microdeletion syndromes, such as 22q11.2 deletion syndrome and 5 p- syndrome, became clinically
available. Due to this rapidly evolving prenatal screening technology, clinicians must make a conscious
effort to keep abreast of the current options; however, the complexity of the testing methods, oftentimes
unclear clinical utility of results, and current lack of professional guidelines for its use renders this task
challenging. To assess physicians’ awareness of, utilization of, and attitudes toward the expanded NIPT
option, 85 Houston, Texas area Obstetrician/Gynecologists (Ob/Gyns) were surveyed. While all
respondents indicated they were aware of NIPT in its traditional form, 75% were aware of the expanded
testing option. Of these respondents, 17% report having elected the expanded testing option when
ordering NIPT. Thirty-nine percent of those surveyed indicated they would feel at least somewhat
uncomfortable explaining the expanded testing option to a patient and, accordingly, 91% expressed that
practitioners need more information regarding the screen. The responding Ob/Gyns indicated that this
new screening option will be increasingly applicable to their future practice, with 28% indicating that they
plan to incorporate the NIPT expanded testing option into their practice in the future. Based on these
findings and the quickly evolving landscape of prenatal screening, education and reeducation of
healthcare professionals is imperative to ensure responsible patient counseling, informed consent, and
appropriate management following test results.
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BACKGROUND
Rapidly evolving prenatal screening technology necessitates that clinicians make a conscious
effort to keep abreast of the evolving testing options. In October 2011, noninvasive prenatal testing
(NIPT) became clinically available. NIPT analyzes cell-free fetal DNA circulating in maternal blood
in order to identify fetuses with chromosomal abnormalities. NIPT in its traditional form screens for
trisomy 21, trisomy 18, trisomy 13, and sex chromosome aneuploidies. NIPT technology was
originally validated in singleton pregnancies at high risk for trisomy 21 due to advanced maternal age,
abnormal serum screen, personal or family history of aneuploidy, and/or abnormal ultrasound.1,2,3
Additional studies have demonstrated a high detection rate for not only trisomy 21 (98-100%), but
also trisomy 18 (97-100%), trisomy 13 (79-92%), monosomy X (94%), and sex chromosome
aneuploidies [47,XXX], [47,XXY], and [47,XYY] (96.2%) in high-risk pregnancies.3,4,5,6 A recent
study determined that NIPT has significantly lower false positive rates and higher positive predictive
values for detection of trisomy 21 and trisomy 18, not only in high-risk pregnancies, but also in
average-risk pregnancies when compared to alternative screening options.7 NIPT has been widely
accepted by professional societies as a clinically valid prenatal screen. However, guidelines and
opinions implore healthcare professionals to employ good clinical judgment and ensure proper
informed consent when offering NIPT to their patients.8,9,10,11
In October 2013, two years after the launch of NIPT, the option became available to screen
for several additional conditions, including other select trisomies and specific syndromes caused by
chromosomal microdeletions, such as 22q deletion syndrome (DiGeorge syndrome) and 5psyndrome (Cri-du-chat syndrome). This expanded testing option utilizes the same technology as
NIPT for aneuploidy, but targets more specific chromosome regions in the case of microdeletion
syndromes. Whether the expanded option is offered as an opt-out or opt-in option is laboratory
dependent.
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As of April 2015, eighteen months after the expanded testing option became clinically
available, there have been no large, prospective studies that address the ability of this technology to
detect additional trisomies and select microdeletion syndromes in maternal serum. However, several
proof of concept studies have demonstrated the technology’s ability to detect subchromosomal
abnormalities 12,13,14,15,16,17,18 In March 2015, a study by Wapner et al. attempted to better assess the
ability of single nucleotide polymorphism (SNP) technology to detect microdeletion syndromes using
a cohort of 358 maternal serum samples and 111 samples generated by PlasmArt, a technology that
utilizes artificial DNA mixtures. Based on these assays, positive predictive values for the examined
microdeletion syndromes range from 3.8% to 17.0%.19 This study illustrates the difficulty in
determining clinical performance of the expanded testing option for many of these rare conditions.
While this new expanded testing option is currently clinically available and easily accessible,
the accuracy and precision of the testing as well as the correct interpretation of results remains
uncertain. This gap between available information and informed interpretation presents physicians
and other healthcare providers with the difficult decision of whether to offer this testing to patients
and how to clinically utilize results. Moreover, position statements on the NIPT expanded testing
option have not been issued by professional societies such as the American Congress of Obstetricians
and Gynecologists (ACOG) or the National Society of Genetic Counselors (NSGC), perhaps due to
the absence of informative data. In the meantime, the Society for Maternal-Fetal Medicine (SMFM)
has advised its members to take caution with expanded NIPT due to the high false-positive rate,
specifying that these tests ideally should be offered only after counseling by a genetic counselor.20
The methods by which physicians receive accurate information regarding the newly available
expanded testing option of NIPT have yet to be determined; however, many physicians presumably
learn about testing options directly from testing laboratories. The influence of pharmaceutical
marketing on physician perception and utilization of prescription drugs has been well established, as
educational presentations and promotional materials sponsored by competing laboratories are
2

effective strategies to increase uptake of products.21,22 With regard to NIPT, marketing materials from
laboratories advertise sensitivity as high as 100% and specificity as high as 99.9% for certain
trisomies and microdeletion syndromes without offering further counseling information, such as the
positive predictive value.23 Although a study that specifically evaluates the effects of marketing for
expanded NIPT has not been identified, the established laboratory marketing influence in other
realms of healthcare suggests that these materials likely impact physician perception and use of
expanded NIPT. It is concerning that physicians may be more inclined to order the expanded NIPT
option as a result of laboratory marketing, possibly without having the opportunity to appreciate the
complex nuances of expanded NIPT.
The apparent uncertainty surrounding the use and interpretation of the expanded testing
option of NIPT is reminiscent of the initial reception of NIPT in its traditional form. During the 2011
interim between the clinical launch of NIPT and professional society endorsement, studies revealed
that many clinicians reported a lack of comprehensive knowledge about NIPT, as well as a desire for
clinical and regulatory guidance.24 Allyse et al. urgently called for validation studies and regulation
on NIPT in clinical practice in order for clinicians to comfortably and appropriately integrate the new
technology.25 Even after professional organizations released guidelines for clinical utilization of NIPT
only in the context of high-risk patients, a study by Musci, et al. reported that 97% of Ob/Gyns offer
NIPT to high-risk patients and 91% offer NIPT to average-risk patients.26 This suggests that even in
the absence of professional organization endorsement, the availability of testing allows for potential
implementation. Healthcare professional education and reeducation to ensure responsible facilitation
of prenatal care for patients is of paramount importance as we proceed in a world where technical
ability outpaces technical knowledge. The objective of this study was to characterize current practices
regarding the expanded NIPT option. This knowledge is necessary in order to determine what, if any,
education is needed and desired by those implementing this new testing option in their practices.
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METHODS
Eligibility included English-speaking physicians who attend Houston area Obstetrical
departmental meetings from September 2014 – February 2015. In order to be included in this study,
respondents must have indicated their primary practice setting to be General Obstetrics and
Gynecology. Information was collected by an anonymous survey, which contained three sections:
demographic information, assessment of awareness of the expanded NIPT option, and description of
Ob/Gyns’ attitudes towards the expanded NIPT option. The survey was distributed either via intraoffice mail or in-person at the beginning of Ob/Gyn section meetings at 12 sites (University of Texas
Health, Baylor College of Medicine, and Kelsey-Seybold Clinic).
Data collected from the surveys was analyzed for all applicable variables using the statistical
analysis software program, STATA (v.13.0, College Station, TX). Descriptive charts and graphs were
created using Microsoft Excel. A comparison between groups was performed using contingency tests
(Chi-squared analysis or Fisher’s exact test) or Kruskal-Wallis tests where appropriate. Statistical
significance was assumed at a Type I error rate of 0.05.
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RESULTS
A total of 118 surveys were distributed, 88 of which were given in-person, and 30 of which
were distributed via intra-office mail. Ninety-two surveys were returned. Seven individuals did not
meet the inclusion criteria of practicing primarily in general Obstetrics and Gynecology and were
excluded from all analysis. Therefore, 111 surveys were distributed to eligible individuals, and the
final sample size for analysis was 85, producing a response rate of 76.6%. The survey questions were
selective in terms of which respondents were eligible to answer each, which resulted in varying
numbers of total responses. Of the 85 general Ob/Gyns, 58% (n=49) were female and 58.3% were
non-Hispanic white. The majority of these (8%, n=68) indicated that they practiced primarily in a
private setting, while the remainder practiced in either an academic (17%, n=14) or a hospital-based
setting (4%, n=3). See Table 1 for complete demographic data. The median time participants
reported practicing in the indicated setting was 12 years (range = 0.13 – 40 years).
Table 1 Demographics of eligible respondents (n=85)
n (%)
Gender
Male

35 (41)

Female

49 (58)

No response

1 (1)

Race
White (non-Hispanic)

49 (58)

Hispanic or Latino

10 (12)

Black or African American

8 (9)

Asian or Pacific Islander

12 (14)

Other

5 (6)

No response

1 (1)

Primary Practice Setting
Private practice

68 (80)

Academic/University Medical Center

14 (16)

Hospital-based

3 (4)
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NIPT knowledge and awareness
All participants indicated that they were aware of NIPT, with only 75% (n=64) reporting that
they were aware of the expanded testing option of NIPT. The majority of those who have ordered
NIPT reported that they were aware of the expanded testing option of NIPT (80%, n=55). This is
compared to those who did not report having ordered NIPT, of whom only 64% (n=7) indicated that
they were aware of the expanded testing option (p = 0.046). As expected, those who order NIPT are
significantly more likely to be aware of the expanded testing option. The majority of participants
(82%, n=69) indicated having ever ordered NIPT and an additional 5% (n=4) responded that they
always refer to an MFM or genetic counselor for NIPT. The median number of NIPT orders per
month was 4 (range = 1-30 orders). Just under half of the participants (49%, n=35) reported never
seeing a positive result. Among the remaining participants, about half had seen only 1 positive result
(51%, n=19) with nearly all (97%, n=36) having seen no more than 5 positive results. Increased risk
for fetal aneuploidy was the most common indication for which Ob/Gyns report ordering NIPT (59%,
n=50). Many physicians also reported ordering NIPT upon patient request (33%, n=28) and/or for all
pregnant patients (15%, n=13). Although not all physicians had seen a positive NIPT result, all who
indicated that they have ordered NIPT provided their first recommendation following a positive
result. Of Ob/Gyns surveyed, 3% (n=2) selected only targeted ultrasound as their first
recommendation. The question instructs participants to choose their first recommendation, yet five
individuals selected multiple responses. All responses were included in analysis, yet some individuals
may make more recommendations than they indicated here since they were instructed to select only
one. Overall, Ob/Gyns report making appropriate recommendations following a positive NIPT result
by offering diagnostic testing (32%, n=22) and/or referrals to specialists (71%, n=49). A summary of
participants’ clinical utilization of NIPT is included in Table 2.
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Table 2 Ob/Gyn responses to questions about clinical utilization of NIPT
n (%)
Before today, were you aware of the expanded testing option of NIPT? (n=85)
Yes

64 (75)

No

12 (14)

I am unsure

9 (11)

If yes, how did you initially learn about the expanded testing option? Check all that
apply. (n=64)
Medical literature

31 (48)

Professional society/conference

15 (23)

Colleague

10 (16)

Marketing from labs that offer it

30 (47)

Educational lecture

12 (19)

Other

2 (3)

If you order NIPT, what lab do you order from? Check all that apply. (n=69)
Sequenom/MaterniT21 Plus

34 (49)

Natera/Panorama

26 (38)

Verinata/Verifi/Illumina

20 (29)

Ariosa/Labcorp/Harmony

30 (44)

Other

7 (10)

I am unsure

4 (6)

It depends on:

10 (15)

No response

1 (2)

For which patients do you order/refer for NIPT? Check all that apply. (n=85)
All patients at increased risk for fetal aneuploidy (maternal age, ultrasound finding,
etc)
Only patients at increased risk for fetal aneuploidy who decline invasive testing

50 (59)

Patients who request it

28 (33)

All pregnant patients

13 (15)

Other

15 (18)

3 (4)

No response

12 (14)

If a patient had a positive NIPT result, what would be your first recommendation? Please
select the best answer. (n=69)
I would offer CVS/amniocentesis
I would recommend a targeted ultrasound

22 (32)
2 (3)

I would refer the patient to a specialist, such as an MFM or genetic counselor
Other

49 (71)
2 (3)
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Expanded NIPT knowledge and awareness
Twelve individuals (14%) reported that they order the expanded testing option when ordering
NIPT; therefore, 17% of respondents who have ordered NIPT have also ordered the expanded testing
option. Only one participant reported having seen a positive expanded NIPT result. Table 3 includes a
summary of the clinical utilization of expanded NIPT. When asked about the indications for which
they order expanded NIPT, half (50%, n=6) of those who do order it reported that they order upon
patient request. When asked what factors prompt Ob/Gyns who do order expanded NIPT to be
selective about the patients for whom they order it, the most common response was insurance
coverage/consideration of whether the patient can afford it (58%, n=7). No participants selected
“running out of time to discuss testing options with the patient,” “feeling that this testing is not in the
best interest of the patient,” or “lack of convenient access to the testing” as factors that influence their
decision not to order expanded NIPT for certain patients. Although participants were instructed to
select their first recommendation for a positive expanded NIPT result, one respondent selected two
answers. All responses were included, but other participants may not have selected all that apply
because they were instructed not to do so. Similarly, only participants who reported ordering
expanded NIPT were instructed to indicate the timing of a referral for expanded NIPT. However, 17
participants who do not currently order expanded NIPT also responded to this question, and their
responses were included. Respondents who order expanded NIPT tended to refer only after receiving
a positive result (83%, n=10) rather than prior to ordering (17%, n=2). Finally, half (50.0%, n=6) of
the respondents who do order expanded NIPT report that they tell patients that the testing is 99-100%
accurate. No respondents selected accuracies lower than 90% or indicated that they do not tell
patients this information.
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Table 3 Ob/Gyn responses to questions about clinical utilization of expanded NIPT
n (%)
For which patients do you order the expanded testing option when ordering NIPT? Check
all that apply. (n=12)
Family history of trisomy 16, trisomy 22, or a microdeletion syndrome

7 (58)

Ultrasound indicative of trisomy 16, trisomy 22, or a microdeletion syndrome

5 (42)

Those who request it

6 (50)

All pregnant patients who pursue NIPT

4 (33)

For those patients for whom you do not order the expanded testing option, what factors
influence your decision not to order it? Check all that apply. (n=12)
Lack of interest from my patient
My patient cannot afford it/it is not covered by their insurance

3 (25)
7 (58)

Not enough published data regarding accuracy

1 (8)

My professional society(ies) have not published guidelines

1 (8)

I order this testing for all of my patients

2 (17)

Other

1 (8)

No response

2 (17)

If a patient had a positive NIPT expanded testing result, what would be your first
recommendation? Please select the best answer. (n=12)
I would offer CVS/amniocentesis

3 (25)

I would refer the patient to a specialist, such as an MFM or genetic counselor

10 (83)

With regard to the NIPT expanded testing option, when do you refer patients to an
MFM/genetic counselor? (n=29)
Prior to ordering the test

13 (45)

Only when patients have a positive result

16 (55)

I am unsure

2 (7)

What do you tell your patients the accuracy is for the NIPT expanded testing option? (n=12)
99-100%

6 (50)

90-98%

3 (25)

I am unsure

2 (17)

No response

1 (8)

Participants were also asked about their perceptions of expanded NIPT in terms of whether
the expanded testing option is in an opt-in or opt-out format, whether they were aware of professional
guidelines for this testing, and whether they plan to incorporate it into their practice in the future
(Table 4). Participants who indicated that they were aware of the expanded testing option of NIPT
9

were asked whether they were aware of professional guidelines concerning expanded testing. Nearly
one-third (31%, n=20) responded that they were aware of such guidelines. All participants who
indicated that they have ordered/referred for NIPT were asked whether their laboratory of choice
offers the expanded portion of NIPT in the opt-in or the opt-out format, and the majority (68%, n=50)
indicated that they were unsure. This is in accordance with the fact that many labs offer certain
conditions within the expanded NIPT option in the opt-in format and certain conditions in the opt-out
format. Finally, half of participants (50%, n=42) reported that they were unsure of whether they plan
to incorporate NIPT expanded testing into their practices in the future.
Table 4 Ob/Gyn responses to questions about perceptions of expanded NIPT
n (%)
Are you aware of professional guidelines concerning the expanded testing option of
NIPT? (n=64)
Yes

20 (31)

No

19 (30)

I am unsure

18 (28)

No response

7 (11)

Does your laboratory of choice offer the expanded testing option in the opt-in or opt-out
format? (n=73)
Opt-in
Opt-out

19 (26)
2 (3)

I am unsure

50 (68)

No response

2 (3)

Do you plan on incorporating the NIPT expanded testing option into your practice in the
future? (n=85)
Yes

24 (28)

I currently order NIPT expanded testing

11 (13)

I am unsure

42 (50)

No

8 (9)
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Attitudes toward expanded NIPT
Participants were asked to share their attitudes toward the expanded testing option of NIPT
by indicating their comfort level explaining the testing to patients using a Likert scale ranging from
very uncomfortable to very comfortable, and by selecting whether they consider expanded testing a
screen or a diagnostic test (Table 5). Participants were divided into those who reported ordering the
expanded testing option of NIPT and those who did not. Only 34% (n=25) of those who did not report
ordering expanded NIPT indicated that they felt at least somewhat comfortable explaining the testing
to patients, whereas the majority (83%, n=10) of those who reported ordering expanded NIPT
indicated that they felt at least somewhat comfortable explaining it to patients (p = 0.012).
Additionally, the majority of participants (68%, n=58) correctly identified that expanded NIPT is a
screen rather than a diagnostic test. When divided into groups based on whether or not they order
expanded NIPT, 14% (n-10) of those who reported that they do not order the expanded testing option
incorrectly identified it as a diagnostic test, compared to 33% (n=4) of those who reported that they
have ordered expanded NIPT who incorrectly identified it as a diagnostic test (p = 0.004). Therefore,
individuals who have ordered expanded NIPT were significantly more likely to
inappropriatelyperceive that it is a diagnostic test rather than a screen.
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Table 5 Ob/Gyn responses to questions about comfort with expanded NIPT (n=85)
n (%)
How comfortable are you with explaining the expanded testing option of NIPT to your
patients?
Very uncomfortable

10 (12)

Somewhat uncomfortable

23 (27)

Neutral

13 (15)

Somewhat comfortable

26 (30)

Very comfortable

9 (11)

No response

4 (5)

Which do you consider the NIPT expanded testing option to be?
A screen

58 (68)

A diagnostic test

14 (17)

Neither

1 (1)

I am unsure

10 (12)

No response

2 (2)

Participants were also asked to react to a series of statements by indicating whether they
agree, disagree, or were unsure (Table 6). In order to further characterize the attitudes of Ob/Gyns
who were previously aware of the expanded testing option of NIPT, the responses were compared to
those of individuals who were not previously aware of the expanded testing option of NIPT. Of those
who were previously aware of the expanded testing option of NIPT, about one-fifth (19%, n=12)
agreed that it provides little added benefit. This was in comparison to those who reported that they
were not aware of expanded NIPT, none of whom agreed that expanded NIPT provides little added
benefit (p = 0.048). Therefore, those who were previously aware of expanded NIPT are more likely to
be wary of its benefit. Additionally, of respondents who were aware of expanded NIPT, about half
(49%, n=31) disagreed with a statement that the testing will replace invasive testing, whereas 18%
(n=2) of those who were not aware of expanded NIPT disagreed with this statement (p = 0.005).
Therefore, those who were previously aware of expanded NIPT were significantly more likely to
perceive that expanded NIPT is not a replacement for diagnostic invasive prenatal testing. Despite
12

comfort level and utilization, an overwhelming majority of participants (91%, n=77) agreed that
practitioners need more information/education about expanded NIPT. This desire for more
information is consistent across all groups of physicians, including those who reported that they have
ordered expanded NIPT and those who have not. Finally, 40% (n=25) of those who were aware of
expanded NIPT agreed that it will become standard of care, whereas over half (56%, n=5) of those
who were not previously aware of expanded NIPT agreed with this statement (p = 0.048). Thus, those
who had previously learned of the expanded testing option of NIPT are less likely to think that it will
become standard of care.
Furthermore, comfort level with explaining expanded NIPT was a significant predictor of
respondents’ attitudes toward expanded NIPT. Of those who were at least somewhat comfortable with
explaining the expanded testing option of NIPT to patients, 37% (n=13) agree that expanded NIPT
will replace invasive procedures. This is compared to just over one quarter (22%, n=7) of those who
reported being either somewhat uncomfortable or very uncomfortable with explaining the testing to
patients and agreed that expanded NIPT will replace invasive testing (p = 0.029). Thus, those who are
more comfortable explaining expanded NIPT to patients are more likely to report that they view
expanded NIPT as a replacement for invasive procedures. Similarly, 41% (n=14) of those who are
either somewhat comfortable or very comfortable explaining expanded NIPT to patients agreed that
clinical utility and validity have been established for NIPT expanded testing. In comparison, only 7%
(n=2) of those who are somewhat uncomfortable or very uncomfortable explaining expanded NIPT
agree that clinical utility and validity have been established for expanded NIPT (p = 0.026). As
expected, those who report more comfort explaining expanded NIPT are more likely to perceive that
the testing has been validated.
Finally, the source from which Ob/Gyns learn about the expanded testing option of NIPT is
suggestive of whether they anticipate incorporating this testing option into their practice in the future.
Although several participants selected multiple sources of information for learning about expanded
13

NIPT, those who selected a single source of academic nature, including medical literature, a
professional society/conference, a colleague, or an educational lecture, were compared to those whose
sole source of information was marketing from labs. Of those who selected a single source of
information about expanded NIPT, the majority (71%, n=10) of those who had learned from only
laboratory marketing were unsure of whether they would incorporate it into their practice in the
future. In comparison, only 19% (n=5) of those who learned from only academic sources were unsure
(p = 0.005). Thus, those who gained information from academic sources were more likely to report
that they had an idea of whether they would incorporate expanded NIPT into their future practices.
Table 6 Ob/Gyn attitudes toward expanded NIPT (n=85)

The NIPT expanded testing option provides little
added benefit
The conditions included in the expanded testing
option were chosen arbitrarily
The NIPT expanded testing option will affect my
practice
The NIPT expanded testing option will replace
invasive procedures
Practitioners need more information/education
about the test/technology
Clinical utility and validity have been established
for NIPT expanded testing
NIPT expanded testing is going to simplify
prenatal diagnosis
Prenatal diagnosis of microdeletion syndromes
reduces lifetime medical costs
The technology used in the NIPT expanded
testing option is applicable to any
microdeletions/duplications in the genome
The NIPT expanded testing option will
eventually be standard of care

Agree
(%)

Unsure
(%)

Disagree
(%)

No response
(%)

12 (14)

30 (35)

41 (48)

2 (3)

5 (6)

34 (40)

43 (51)

3 (3)

29 (34)

28 (33)

25 (29)

3 (4)

25 (30)

23 (27)

35 (41)

2 (2)

77 (91)

3 (3)

2 (2)

3 (4)

19 (22)

47 (55)

15 (18)

4 (5)

32 (38)

33 (39)

15 (17)

5 (6)

29 (34)

41 (48)

12 (14)

3 (4)

11 (13)

48 (56)

22 (26)

4 (5)

30 (35)

45 (53)

6 (7)

4 (5)
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DISCUSSION
To date, this is the first known study to examine Ob/Gyns’ awareness of, clinical utilization
of, and attitudes toward the novel expanded NIPT option, based on a systematic search of medical
literature using the search engine PubMed and the search terms “NIPT,” “microdeletion,” “cell free,”
and/or “utilization” in April 2015. This study identified that the majority of Ob/Gyns surveyed were
aware of the expanded NIPT option, yet few actually have utilized it in clinical practice. Physicians
surveyed have expressed a strong desire for more information regarding the expanded NIPT option.
Given the lack of published large validation studies and professional guidelines, ethical controversy
and apprehension surround the widespread utilization of the expanded testing option.27 Proof of
concept studies using no more than 16 affected pregnancy plasma samples to demonstrate the
technical ability to detect subchromosomal abnormalities in maternal serum, and larger studies using
artificial DNA mixtures have attempted to characterize the validity of expanded NIPT.1,19,28 However,
the low incidence of each condition renders the positive predictive value extremely low, despite
projected high sensitivity and specificity rates.
This study demonstrated that almost half (46.9%) of those who reported awareness of the
expanded NIPT option had heard about it from marketing from labs. While education from labs can
benefit ordering physicians and encourage them to learn more about prenatal testing options,
currently available marketing materials from labs may not provide a full picture of the implications of
this screen. For example, laboratory pamphlets cite an up to 99.5% sensitivity and >99% specificity
for 22q11 deletion syndrome, but they do not include information explaining that by factoring in a
population prevalence of 1/2,000, the positive predictive value is low (less than 5%).23 This study
revealed that although many Ob/Gyns are receiving information about expanded NIPT from labs,
participants were more likely to plan to incorporate expanded NIPT into their practices in the future if
they had learned about it from an academic source. The survey did not ask what sources physicians
prefer to receive information from, but these results would support the hypothesis that physicians
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prefer to learn about the expanded testing option from academic sources, such as medical literature,
professional societies, colleagues, or educational lectures.
Although no professional guidelines specific to expanded NIPT have been published,
guidelines for similar screening should be relied upon for direction when new testing becomes
available. A joint statement by the American College of Medical Genetics (ACMG), the Perinatal
Quality Foundation (PQF), ACOG, NSGC, and SMFM on expanded carrier screening cautions that if
residual risk information has not been determined, lab reports should clearly communicate the
limitations of interpretation of screening.29 This guideline calls upon laboratories and healthcare
professionals to communicate the results of carrier screening to patients in a realistic manner. It is
reasonable to think that discussion surrounding expanded NIPT should follow suit with the same
urgency. Because communication between physicians and patients is crucial, this study investigated
Ob/Gyns’ understanding of the expanded NIPT option. When asked about the accuracy of the
expanded testing option that they quote to patients, the majority of participants who have ordered
expanded NIPT quote 90% or greater. The word “accuracy” was used in this question in order to
prevent confusion between mores specific terms such as sensitivity or positive predictive value.
Although the term “accuracy” was intentionally ambiguous in order to capture a number that
Ob/Gyns may realistically discussed with patients, this question is limited to the participants’
interpretations of the term “accuracy.” This study provided further insight into Ob/Gyns’ confidence
in expanded NIPT results, revealing that seventeen percent of respondents incorrectly indicated that
expanded NIPT is a diagnostic test. This finding parallels a finding from Benn, et al., which reported
that nearly half of Ob/Gyns view traditional NIPT as a full substitute for invasive testing.30
However, the majority of physicians report making proper recommendations following a
positive result, including offering invasive, diagnostic testing and/or a referral to a specialist such as
an MFM or genetic counselor. Even if patients eventually receive the recommended care, it is
preferable that patients receive accurate and appropriate information prior to testing for purposes of
16

both informed consent and prevention of psychological harm. This concept of knowledgeable pre-test
counseling is particularly pertinent to expanded NIPT due to the complex nature of the technology
and the often unfamiliar information it can produce. The model in which comprehensive information
is provided only following a positive result is consistent with a trend in which technological ability to
perform tests surpasses understanding of its validity, utility, and best practices. For this reason, the
education of healthcare professionals who provide information about expanded NIPT to patients is
crucial. Practitioners must consider whether the ability to prenatally screen for subchromosomal
abnormalities, or other genetic conditions, is sufficient basis for performing the testing.
A strength of this study is that during the study period, no major publications regarding the
clinical utility or validity of expanded NIPT were published, nor were professional guidelines
published during the study period. No new major laboratories began offering expanded NIPT, and no
new types of genetic conditions were added to testing panels during the study period. Thus, the
information and testing options available to participants was consistent. Furthermore, responses from
particular respondents indicated consistent representation of knowledge and awareness. Few
individuals skipped questions to which they were instructed to respond. This suggests that the
responses gathered from the survey accurately represent the perceptions and attitudes of participants.
Limitations to this study include the fact that since some questions which asked for the best
response received multiple responses, some questions may not have been interpreted by participants
as intended. In addition, some participants responded to questions in sections that they should not
have completed due to selection. When possible, all potentially relevant responses were included in
analysis and those obviously in discordance with the intent of the question were excluded. Another
limitation to this study is the number of participants. Although the sample size did exceed the
expected number, surveying a larger number of Ob/Gyns would provide further understanding of
clinical utilization of the expanded NIPT option. Similarly, this study population was limited to
Ob/Gyns who attended Obstetrical departmental meetings at large, urban hospitals and clinics in
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Houston, Texas. The majority (80%) of this study population reported practicing primarily in a
private setting. Therefore, it may be difficult to generalize these findings to Ob/Gyns from other
geographical areas and diverse practice settings. Despite this limitation, the physicians included in
this study who attend meetings and take the initiative to fill out a survey may be more likely to be
familiar with the expanded testing option and more motivated to learn more about it. Therefore, this
limitation may suggest that the results of this study underestimate the need and desire for physician
education regarding expanded NIPT.
Future directions for study may include investigating the way that healthcare professionals
present information regarding the expanded NIPT option to patients and whether the nuances of
“accuracy” are discussed in detail, as the results of this study call into question the language used in a
clinical setting. Characterizing how phsyicians discuss the reliability of a screen in a pre-test
counseling setting would help to determine how information can be best communicated to healthcare
professionals when providing education. Additionally, this study reveals that while less than half of
Ob/Gyns report being at least somewhat comfortable explaining expanded NIPT to patients, they are
aware of the gaps in their knowledge about this prenatal screen and unequivocally desire more
information about it. Thus, future investigation should include assessment of how physicians desire to
learn this information. Since the participants were accessed through Obstetrical departmental
meetings, educational presentations by knowledgeable colleagues at these meetings may be a good
starting point. What remains unknown is how best to access those providers not attending section
meetings who are potentially being informed by laboratory representatives only. Ob/Gyns are
ordering the expanded NIPT option and will presumably continue to do so, and the development of
further professional guidelines for utilizing expanded NIPT is increasingly vital. Healthcare
professionals have a responsibility to educate each other regarding the expanded NIPT option and
other prenatal screens in order to ensure that patients receive optimal care.
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